Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology)

Barcelona 08916

0 studies enrolling now · 1 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma, Lung Cancer Non Small Cell, Urothelial Carcinoma Bladder

Studies at this site

• IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC — Completed